Think single-serve sachets, RTD cans, and benefits that emphasise morning focus, post-meal digestion, and evening wind-down. The key is for tea and coffee companies to communicate to these consumers how their beverages fit into the lifestyle of the GLP-1 users
This was demonstrated in two randomised controlled trials (RCTs) that showed a decrease in epicardial adipose tissue in patients with T2D and obesity on liraglutide and exenatide according to echocardiography and cardiac MRI
While both are highly effective, they have key differences in how they work, their effectiveness, and their side effect profiles
Semaglutide is a prescription medication and is not appropriate for everyone
Physiological complexities To address the rebound effect, patients and researchers must first understand that obesity is a chronic, complex disease 2 that GLP-1 agonists alone will not quickly fix